Physician profile
Mark Ash
NPI 1710419379
$11,366.95
in general payments reported to CMS, 2019-2025
23 companies · $2,139 in 2025
The $2,139 reported for 2025 was more than what 77% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $506 · 2022: $2,704 · 2023: $2,716 · 2024: $3,301 · 2025: $2,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,874 · Education: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,874.29 |
| Education | $282.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,905.92 | 2021-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $1,180.84 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Incyte Corporation | $992.21 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $891.31 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $864.64 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $851.69 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $719.05 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Leo Pharma INC. | $639.95 | 2022-2025 | Adbry |
| Pfizer INC. | $533.89 | 2021-2025 | |
| Lilly USA, LLC | $495.86 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Dermavant Sciences, INC. | $456.36 | 2022-2024 | Vtama |
| Ucb, INC. | $446.42 | 2022-2025 | Bimzelx, Cimzia |
| Amgen INC. | $406.33 | 2021-2024 | Otezla |
| Arcutis Biotherapeutics, INC. | $236.08 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $218.14 | 2022-2025 | Sotyktu |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $199.20 | 2021-2025 | Nemluvio, Aklief |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.28 | 2022-2025 | Spevigo |
| Janssen Scientific Affairs, LLC | $45.53 | 2023 | |
| Paratek Pharmaceuticals, INC. | $21.75 | 2025 | Nuzyra |
| Organon LLC | $21.18 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $19.71 | 2021 | |
| Biofrontera INC. | $17.10 | 2021 | |
| Ascensia Diabetes Care US INC. | $13.51 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.